<DOC>
	<DOCNO>NCT03105375</DOCNO>
	<brief_summary>The purpose study assess analyze safety , tolerability PK/PD data follow single ascend multiple ascend dos X842 healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics X842 Human : A Single/Multiple Ascending Dose Study</brief_title>
	<detailed_description>This single-centre , open label , first-in-human study primary objective evaluate safety tolerability X842 administration single multiple oral ascending dose healthy male female subject . The study comprise Single Ascending Dose ( SAD ) part Multiple Ascending Dose ( MAD ) part include open-label multiple dose cohort administer active comparator ( omeprazole ) . Four subject include SAD MAD cohort .</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Willing able give write informed consent participation study . Body Mass Index ( BMI ) ≥ 18 ≤ 30 kg/m2 weight least 50 kg 100 kg screening . Clinically normal medical history , physical finding , vital sign , ECG laboratory value time screening , judge Investigator . Male subject must willing use condom fertile partner , must use contraceptive method failure rate &lt; 1 % prevent pregnancy drug exposure partner refrain donate sperm date dose three month dose IMP . Female subject must nonchildbearing potential ( define premenopausal female document tubal ligation hysterectomy ; postmenopausal female define 12 month amenorrhoea [ questionable case blood sample simultaneous follicle stimulation hormone 25140 IE/L estradiol &lt; 200 pmol/L confirmatory ] ) . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . Present clinically significant psychiatric diagnosis , discretion Investigator . Any clinically significant illness , medical/surgical procedure trauma within four week first administration investigational medical product . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past five year , regardless whether evidence local recurrence metastasis . History surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . The investigator guide evidence following : history major gastrointestinal surgery gastrectomy , gastroenterostomy , bowel resection Transjugular Intrahepatic Portosystemic Shunt ( TIPS ) . History presence diagnose longterm treatment GERD . Likelihood gastric pH &gt; 2 due example know autoimmune gastritis know Helicobacter pylorus gastritis . Known severe atrophic gastritis . Vitamin B12 deficiency and/or chronic Vitamin B12 substitution . Known malabsorption . Any planned major surgery within duration study . Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody Human Immunodeficiency Virus ( HIV ) . After 10 minute supine rest time screening , vital sign value outside follow range : Systolic BP 90 140 mm Hg Diastolic BP 50 90 mm Hg Heart rate ( HR ) 4590 beat per minute Prolonged QTcF ( &gt; 450 m ) , cardiac arrhythmia clinically significant abnormality rest ECG time screening , judge Investigator . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge Investigator , history hypersensitivity drug similar chemical structure class X842 omeprazole . Regular use prescribe nonprescribed medication include antacid , analgesic , herbal remedy , vitamin mineral within two week prior ( first ) administration IMP , except occasional intake paracetamol ( maximum 2 000 mg/day ; exceed 6 000 mg/week ) , discretion Investigator nasal decongestant without cortisone antihistamine maximum 10 day , discretion Investigator . Administration another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment less three month administration last dose first dose IMP study . Subjects consent screen dose previous phase I study exclude . Current smoker user nicotine product . Irregular use nicotine ( e.g . smoking , snuffing , chew tobacco ) less three time per week allow screening visit . Positive screen drug abuse alcohol screen admission unit prior administration IMP . Current history alcohol abuse and/or use anabolic steroid drug abuse . Intake xanthine and/or taurine contain energy drink within two day prior first day IMP administration . Plasma donation within one month screen blood donation ( correspond blood loss ) three month prior screen . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Potassium competitive acid blocker</keyword>
	<keyword>X842</keyword>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>Esophagitis</keyword>
	<keyword>Intragastric pH</keyword>
	<keyword>Acid inhibition</keyword>
</DOC>